Drug Trial Radar · NCT06639997
Safety and Tolerability of AZD5148 in Japanese Participants
Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Oct 31, 2024
Primary completion
Dec 25, 2025
Study completion Dec 25, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure safety, tolerability and PK of a single dose of AZD5148 administered via IV bolus or IM injection in healthy Japanese participants.
Conditions
- Clostridioides Difficile Infection
Interventions
AZD5148Drug
Participants will receive AZD5148 as IM injection or IV bolus
PlaceboDrug
Participants will receive matching doses of placebo as an IM injection or IV bolus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Japanese participants with adverse events (AEs).Time frame: From Randomization (Day -1 or Day 1) to Day 91
- Number of participants with serious adverse events (SAEs)Time frame: From Screening (Day -28 to Day -2) to final Follow-up Visit (Day 361)
- Number of participants with adverse events of special interest (AESIs)Time frame: From Randomization (Day -1 or Day 1) to final Follow-up Visit (Day 361)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Sumida-ku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.